The results of the patient’s baseline PDC NGS and the PDC drug sensitivity test are shown in Figure 4E. The baseline PDC NGS results were consistent with the tumor NGS data; they also showed a BRAF V600E mutation without an ALK fusion. Here, ALK is linked to neoplasm.